Annie A. Smelter
Research Subjects
Annie A. Smelter has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Luke Norton
Diabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA; Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA
2 shared publications - Anna Zagorska
Gilead Sciences, Foster City, USA
1 shared publication - Christopher E. Shannon
Diabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, USA
1 shared publication - Christopher Raymond Frei
University of Texas at Austin
1 shared publication - Dan F. Smelter
University of Texas at Austin
1 shared publication Edgar A. Hinostroza
Diabetes Division, Department of Medicine, University of Texas Health San Antonio, San Antonio, USA
1 shared publication
Latest Publications
- Open Access
- 17 September 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 101, 102253
Are we giving too much weight to lean mass loss?
- 17 September 2025
- Published by Elsevier in Molecular Metabolism
- Vol. 101, 102253
Open AccessAre we giving too much weight to lean mass loss?
- Open Access
- 6 May 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (3)
Successful clearance of persistent Staphylococcus aureus pneumonia with high-dose continuous infusion cefazolin
Background: Deep-seated Staphylococcus aureus infections are difficult to treat and require appropriate antibiotic regimens for clinical success. Recent studies have shown that continuous infusion (CI) of β-lactam antibiotics is associated with reduced mortality, though optimal dosages remain to be determined. Here, we present a case in which high-dose cefazolin, at 10 g daily CI, was used to safely and successfully clear methicillin-susceptible S. aureus (MSSA) pneumonia. Case Summary: A 33-year-old male was admitted to the medical intensive care unit with suspected MSSA community-acquired pneumonia. Over the course of a 43-day hospital stay, the patient’s pneumonia relapsed twice following two 5- to 7-day courses of cefazolin 8 g daily CI. Clearance of the pneumonia was achieved after a 14-day course of cefazolin 10 g daily CI, and the patient was discharged. Conclusion: Here, we describe a patient with incomplete clearance of MSSA pneumonia despite two 5- to 7-day courses of cefazolin 8 g daily CI. Following a 14-day course of cefazolin 10 g daily CI, the patient’s fever and leukocytosis rapidly resolved without direct evidence of drug-related toxicity. This case report provides evidence for the safe and effective use of high-dose cefazolin CI in the clearance of persistent MSSA pneumonia.
- 6 May 2025
- Published by American Society for Microbiology in ASM Case Reports
- Vol. 1 (3)
Open AccessSuccessful clearance of persistent Staphylococcus aureus pneumonia with high-dose continuous infusion cefazolin
Background: Deep-seated Staphylococcus aureus infections are difficult to treat and require appropriate antibiotic regimens for clinical success. Recent studies have shown that continuous infusion (CI) of β-lactam antibiotics is associated with reduced mortality, though optimal dosages remain to be determined. Here, we present a case in which high-dose cefazolin, at 10 g daily CI, was used to safely and successfully clear methicillin-susceptible S. aureus (MSSA) pneumonia. Case Summary: A 33-year-old male was admitted to the medical intensive care unit with suspected MSSA community-acquired pneumonia. Over the course of a 43-day hospital stay, the patient’s pneumonia relapsed twice following two 5- to 7-day courses of cefazolin 8 g daily CI. Clearance of the pneumonia was achieved after a 14-day course of cefazolin 10 g daily CI, and the patient was discharged. Conclusion: Here, we describe a patient with incomplete clearance of MSSA pneumonia despite two 5- to 7-day courses of cefazolin 8 g daily CI. Following a 14-day course of cefazolin 10 g daily CI, the patient’s fever and leukocytosis rapidly resolved without direct evidence of drug-related toxicity. This case report provides evidence for the safe and effective use of high-dose cefazolin CI in the clearance of persistent MSSA pneumonia.
- Open Access
- 10 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
The Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis
The molecular mechanisms regulating the zonal distribution of metabolism in liver are incompletely understood. Here we use single nuclei genomics techniques to examine the spatial transcriptional function of transcription factor 7-like 2 (TCF7L2) in mouse liver, and determine the consequences of TCF7L2 transcriptional inactivation on the metabolic architecture of the liver and the function of zonated metabolic pathways. We report that while Tcf7l2 mRNA expression is ubiquitous across the liver lobule, accessibility of the consensus TCF/LEF DNA binding motif is restricted to pericentral (PC) hepatocytes in zone 3. In mice expressing functionally inactive TCF7L2 in liver, PC hepatocyte-specific gene expression is absent, which we demonstrate promotes hepatic cholesterol accumulation, impaired bile acid synthesis, disruption to glutamine/glutamate homeostasis and pronounced dietary-induced hepatic fibrosis. In summary, TCF7L2 is a key regulator of hepatic zonal gene expression and regulates several zonated metabolic pathways that may contribute to the development of fibrotic liver disease.
- 10 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Open AccessThe Spatial Transcriptional Activity of Hepatic TCF7L2 Regulates Zonated Metabolic Pathways that Contribute to Liver Fibrosis
The molecular mechanisms regulating the zonal distribution of metabolism in liver are incompletely understood. Here we use single nuclei genomics techniques to examine the spatial transcriptional function of transcription factor 7-like 2 (TCF7L2) in mouse liver, and determine the consequences of TCF7L2 transcriptional inactivation on the metabolic architecture of the liver and the function of zonated metabolic pathways. We report that while Tcf7l2 mRNA expression is ubiquitous across the liver lobule, accessibility of the consensus TCF/LEF DNA binding motif is restricted to pericentral (PC) hepatocytes in zone 3. In mice expressing functionally inactive TCF7L2 in liver, PC hepatocyte-specific gene expression is absent, which we demonstrate promotes hepatic cholesterol accumulation, impaired bile acid synthesis, disruption to glutamine/glutamate homeostasis and pronounced dietary-induced hepatic fibrosis. In summary, TCF7L2 is a key regulator of hepatic zonal gene expression and regulates several zonated metabolic pathways that may contribute to the development of fibrotic liver disease.